Masuishi, Toshiki http://orcid.org/0000-0002-7521-1596
Tsuji, Akihito
Kotaka, Masahito
Nakamura, Masato
Kochi, Mitsugu
Takagane, Akinori
Shimada, Ken
Denda, Tadamichi
Segawa, Yoshihiko
Tanioka, Hiroaki
Hara, Hiroki
Sagawa, Tamotsu
Watanabe, Takanori
Takahashi, Takao
Negoro, Yuji
Manaka, Dai
Fujita, Hideto
Suto, Takeshi
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
Article History
Received: 30 March 2020
Revised: 28 July 2020
Accepted: 14 August 2020
First Online: 31 August 2020
Ethics approval and consent to participate
: JACCRO institutional review board approved the present study (approval number: 2013-3). All patients provided written informed consent prior to participation. We conducted this study in accordance with the Declaration of Helsinki.
: All patients enrolled in the present study provided written informed consent for publication prior to participation.
: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
: Toshiki Masuishi reports personal fees from Takeda, Chugai, Merck BioPharma, Taiho, Bayer, Lilly Japan, Yakult Honsha and Sanofi, grants from MSD, Daiichi Sankyo and Ono, outside the submitted work. Akihito Tsuji reports personal fees from Merck Serono Co., Ltd., during the conduct of the study, Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sanofi Corporation and Bristol-Myers Squibb-Corporation, grants from Taiho Pharmaceutical Co., Ltd., Sanofi Corporation, Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc, Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., MSD Corporation and Takeda Pharmaceutical Company Limited and grants from Toray Medical Co., Ltd. and Daiichi Sankyo Co., Ltd., outside the submitted work. Masahito Kotaka reports personal fees from Chugai Pharmaceutical and Yakult Honsya, Takeda Pharmaceutical, Merck Biopharma, Taiho Pharmaceutical, Lilly and Sanofi, outside the submitted work. Masato Nakamura reports personal fees from Merck, Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Takeda Pharmaceutical Company Limited, Taiho Pharmaceutical, Otsuka Pharmaceutical, Sanofi and ONO Pharmaceutical Co., Ltd., outside the submitted work. Yoshihiko Segawa reports personal fees from Japanese Society of Medical Oncology and Taiho Pharmaceutical Co., Ltd., grants from Kindai University, Taiho Pharmaceutical Co., Ltd., Novartis Pharma K.K. and Eisai Co., Ltd., outside the submitted work. Hiroki Hara reports grants from Astrazeneca, grants and personal fees from Daiichi Sankyo, grants from Dainippon Sumitomo Pharma, personal fees from Lilly, grants from Merck Biopharma, grants and personal fees from MSD, Taiho and Chugai, grants from Eisai, LSK BioPharma, Incyte, Pfizer, Boehringer-Ingelheim and Beigene, grants and personal fees from ONO and BMS, personal fees from Yakult Honsha, Sanofi and Takeda, grants from Astellas and personal fees from Kyowa Hakko Kirin, outside the submitted work. Takao Takahashi reports grants from Yakult Honsha Co., Ltd., during the conduct of the study, personal fees from Takeda Pharmaceutical Co., Ltd. and Sanofi Co., Ltd., outside the submitted work. Wataru Ichikawa reports grants and personal fees from Chugai Pharma, Taiho Pharmaceutical and Takeda, personal fees from Daiichi Sankyo, grants and personal fees from Merck Serono, personal fees from Yakult and Bayer Yakuhin, grants from Eizai and Shionogi and grants and personal fees from Ono Pharmaceutical, outside the submitted work. Mitsugu Kochi, Akinori Takagane, Ken Shimada, Tadamichi Denda, Hiroaki Tanioka, Tamotsu Sagawa, Takanori Watanabe, Yuji Negoro, Dai Manaka, Hideto Fujita, Takeshi Suto, Masahiro Takeuchi, Masashi Fujii report declaration of interest: none.
: Japan Clinical Cancer Research Organization (JACCRO).